MLYS Mineralys Therapeutics, Inc. Common Stock

XNAS 16.23 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

MLYS $16.23 —
Key stats
$16.23
52-Week Range
$14.91 – $47.65
YTD
-54.56%
IV Rank (30D)
99.31
Straddle Price
$3.88
P/C Vol Ratio
0.64
Market Cap
$1.4B
Open
$15.92
Day Range
$15.20 – $16.40
Volume
1,768,127
Prev Close
$15.33
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.90%
Beta vs SPY1.41
Cost of Equity (CAPM)12.66% (VRP-adj)
WACC12.08%
Volatility Risk Premium+74.5pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-63.4%
Book / Price42.4% — banking bias active (P/B is primary)
Debt / Equity0.18
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$23.77 (Market Anchor value)
SMA 20 / Bollinger Mid$19.66
Bollinger Width / SMA2048.1% (drives anchor stability)
Net Debt$-0.0B
Market Cap$1B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
81%
20-Day Fair Value
≈ by Dec 8, 2026
$16.27
α +0.7% rank 84%
conviction
47%
40-Day Fair Value
≈ by Jan 6, 2027
$16.74
α +3.5% rank 88%
conviction
86%
60-Day Fair Value
≈ by Feb 4, 2027
$16.81
α +4.0% rank 84%
conviction
81%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 42.2× · 3 peers
Peer EV/EBITDA n/a 0% median 21.2× · 3 peers
Peer P/B $25.10 22% median 3.9× · 3 peers
Peer P/S n/a 0% median 4.1× · 3 peers
Market Anchor (SMA50) $23.77 78% stability 71% (BB-width)
Options Expected (B-L 30d) $13.88 0% 9 strikes · skew +0.59
As of 2026-11-09 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$1.4B
Employees
76
List Date
2023-02-10
CIK
0001933414
Last Earnings
Nov 4 after close · −10.4% vs ±24.3% expected
Headquarters
Radnor, PA
Homepage
https://mineralystx.com

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduc…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'23'24'25'26Avg
Jan--25.69%-15.92%-13.50%-1.24%
Feb-3.58%21.10%-7.96%-5.22%1.09%
Mar-11.82%-15.84%77.63%-7.61%10.59%
Apr-12.43%-5.99%2.67%0.91%-3.71%
May6.44%-0.23%4.14%7.66%4.50%
Jun17.83%-10.55%-13.82%-13.28%-4.96%
Jul-11.52%1.81%3.28%-5.90%-3.08%
Aug-7.29%2.99%13.28%-0.43%2.14%
Sep-26.39%1.34%31.39%-1.72%1.16%
Oct-15.33%8.96%2.64%-23.36%-6.77%
Nov-14.06%-5.06%10.08%3.89%*-1.29%
Dec19.44%-8.75%-10.92%---0.08%
Total-51.00%7.80%95.97%-47.68%1.27%
* Only 4 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $19.35
SMA 50: $23.59
SMA 200: $26.50
Current: $16.17
EMA 12: $17.71
EMA 26: $19.87
MACD: -2.1618 | Signal: -0.3070
BEARISH
ADX (14): 28.28
TREND
+DI: 20.03
−DI: 30.98

Momentum Oscillators

RSI (14): 33.45
NEUTRAL
Stoch %K: 7.81
Stoch %D: 9.71
Williams %R: -83.36

Volume & Volatility

BB Upper: $24.16
BB Lower: $14.55
NEUTRAL
OBV: 9,712,690
Vol SMA 20: 1,891,362
Vol ROC: 121.87%
ATR: $1.45
True Range: $1.20
HV 20: 101.4%
HV 30: 88.5%
HV 60: 78.1%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis

MLYS (Mineralys Therapeutics) - Comprehensive Stock Analysis

Executive Summary

Overall Assessment: BEARISH with confidence level 8/10

Key Drivers & Primary Risks:

  • Primary Driver: Severe technical deterioration with stock trading 42% below 200-day MA ($26.58 vs current $15.33), coupled with deeply oversold momentum indicators suggesting capitulation or significant fundamental concerns
  • Primary Risk: Despite positive clinical trial news (Lorundrostat data presentations), the stock price collapse indicates market skepticism about clinical efficacy, commercial viability, or pipeline advancement; high beta (1.68) amplifies downside risk in risk-off environments

Investment Thesis: Mineralys is a clinical-stage biotech showing positive trial data momentum for lorundrostat in hypertension/CKD (three presentations in October-November 2026), yet the market has aggressively repriced the stock downward, suggesting either unfavorable trial details, competitive pressure, or funding concerns. The extreme oversold technical condition creates a potential mean-reversion bounce opportunity, but the fundamental backdrop remains unclear without recent earnings details.

Recent News Sentiment Impact: Positive clinical presentations (4 out of 6 recent headlines positive) have failed to arrest the stock's decline, indicating the market is either (1) front-running negative results not yet disclosed, (2) pricing in commercial challenges despite efficacy, or (3) focused on a separate negative catalyst (funding, dilution, or pipeline setback). This disconnect between positive news sentiment and bearish price action is a major red flag.

Technical Analysis

Trend Direction

| Timeframe | Status | Analysis | |-----------|--------|----------| | Short-term (1-4 weeks) | STRONG DOWNTREND | Price at $15.33 is 22% below Lower Bollinger Band ($14.93), 42% below 200-day MA, below all major moving averages (SMA20: $19.66, SMA50: $23.77). ADX 28.80 confirms strong directional trend; -DI 32.93 >> +DI 17.33 shows sellers dominating. | | Medium-term (1-3 months) | DOWNTREND | All exponential moving averages aligned bearishly (price $15.33 < EMA12 $17.99 < EMA26 $20.17). No sign of inflection point. | | Long-term (3-12 months) | SEVERE DOWNTREND | Stock has collapsed 42% from its 200-day MA anchor, suggesting either a fundamental repricing or extended washout. |

Support/Resistance Levels

| Level | Price | Significance | |-------|-------|--------------| | Immediate Support (Critical) | $14.93 | Lower Bollinger Band; breaking below would signal breakdown below oversold bands | | Next Support | $14.00 (estimated) | Psychological level; potential capitulation point | | Strong Resistance (Short-term) | $19.66 | SMA 20; would require 28% rally to reclaim; key near-term ceiling | | Intermediate Resistance | $23.77 | SMA 50; would represent partial recovery (55% from current price) | | Major Resistance (Recovery) | $26.58 | 200-day MA; breakout above this signals end of downtrend |

Momentum Signals

RSI (14): 28.63 — OVERSOLD (Extreme)

  • Reading below 30 indicates capitulation selling; typically precedes either sharp reversal OR continued washout
  • This deep reading suggests exhaustion but does NOT guarantee immediate reversal in biotech, where fundamental catalysts drive price action
  • Caution: Oversold biotech stocks can remain oversold for extended periods during clinical/commercial crises

Stochastic %K: 10.04 / %D: 10.93 — EXTREME OVERSOLD

  • Both readings below 20 indicate extreme oversold condition; typically reverses within days to weeks
  • However, stochastic can persist in oversold territory for 3-5+ days without triggering bounce

Williams %R: -94.45 — EXTREME OVERSOLD

  • Reading below -80 indicates exhaustion; above -20 would signal overbought
  • Current -94.45 is near worst-case readings, suggesting capitulation has occurred

MACD: -2.18 vs Signal -0.40, Histogram -1.78 — BEARISH

  • MACD below signal line indicates downward momentum continuation
  • Histogram at -1.78 and widening suggests momentum is accelerating downward, NOT decelerating
  • Critical divergence: Despite RSI/Stochastic oversold conditions, MACD shows no sign of bullish crossover imminent

Bollinger Bands

  • Upper Band: $24.38 | Middle (SMA 20): $19.66 | Lower Band: $14.93
  • Width: 48.08 (moderate bandwidth, not in extreme squeeze)
  • Signal: NEUTRAL zone per the data, but price is squeezed near lower band — typical mean-reversion setup
  • Interpretation: Stock is 1.5 standard deviations below the 20-day moving average; historical tendency is mean reversion back toward $19.66 within 5-10 trading days, but this assumes no new negative catalyst

Volume Analysis

  • Current Volume SMA 20: 1,853,225 shares/day
  • Volume Rate of Change: +22.56% — elevated volume in recent trading
  • On-Balance Volume: 8,275,965 (trending negative based on price structure)
  • Interpretation: Elevated volume accompanying downtrend confirms institutional and retail capitulation; heavy selling pressure. Volume surge on down days without reversal suggests continued selling interest.

News & Sentiment Analysis

Recent Headlines Summary (Last 10 Articles Reviewed)

Dominant Theme: Lorundrostat clinical development progress in hypertension and chronic kidney disease

  • Article 1 (Oct 29, 2026): Obstructive Sleep Apnea competitive landscape expansion — Neutral, broad industry coverage
  • Article 2 (Oct 22, 2026): Lorundrostat data in hypertension + CKD at ASN Kidney Week — Positive
  • Article 3 (Oct 9, 2026): Lorundrostat data at AHA Hypertension Scientific Sessions — Positive
  • Article 4 (Oct 2, 2026): Lorundrostat data announcement for ASN Kidney Week — Positive (pre-presentation)
  • Article 5 (Sep 16, 2026): Hypertension clinical trial pipeline acceleration (100+ companies) — Positive (industry backdrop)
  • Article 6 (Jun 8, 2026): Late-breaking lorundrostat data at ENDO 2026 — Positive

Sentiment Aggregate: 4 out of 6 recent headlines POSITIVE, 1 NEUTRAL, 0 NEGATIVE

Sentiment Assessment: Positive (at headline level) vs. Bearish (at price level)

Critical Mismatch: News sentiment is POSITIVE (clinical progress, data presentations), yet stock has collapsed 42% from 200-day MA. This suggests:

  1. Market expected better data — The presentations may contain efficacy/safety concerns not captured in headline sentiment
  2. Competitive concerns — OSA landscape note (Article 1) hints at crowded pipeline; lorundrostat may face headwinds from superior competitors
  3. Commercial viability questions — Even if efficacy is good, market may question commercial potential (pricing, reimbursement, market size)
  4. Funding/dilution fears — Possible unannounced capital raise or financing concerns driving institutional selling

Catalyst Identification

Immediate (1-7 days):

  • No announced catalysts; post-earnings period (most recent: Nov 4, 2026)

Near-term (1-4 weeks):

  • Earnings call discussion of Lorundrostat trials and next milestones (already reported Nov 4 — potential catalyst already passed)
  • Any management commentary on funding runway, partnership interest, or trial timeline

Medium-term (1-3 months):

  • Phase 2b/Phase 3 Lorundrostat results (exact timing unknown from provided data)
  • FDA feedback or regulatory guidance on lorundrostat approval pathway
  • Competitive product announcements in hypertension/CKD space
Generated
Earnings History
12 of 12 under expected move
Avg Expected Move
24.83%
Avg Actual Move
5.38%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-03-21 After-Close 21.39% 1.91% 0.09x Within
2024-05-09 After-Close 37.35% 5.26% 0.14x Within
2024-08-13 Pre-Market 44.09% 4.32% 0.10x Within
2024-11-12 After-Close 24.29% 6.95% 0.29x Within
2025-02-12 Pre-Market 45.55% 10.04% 0.22x Within
2025-05-12 After-Close 15.66% 1.20% 0.08x Within
2025-08-12 After-Close 15.54% 0.37% 0.02x Within
2025-11-10 Pre-Market 21.37% 17.04% 0.80x Within
2026-03-12 Pre-Market 15.46% 3.50% 0.23x Within
2026-05-06 After-Close 21.75% 2.56% 0.12x Within
2026-08-11 After-Close 11.25% 1.02% 0.09x Within
2026-11-04 After-Close 24.26% 10.35% 0.43x Within

Earnings calendar: this week’s reports with expected vs actual moves →

MLYS Options Activity & IV Rank

MLYS IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 121.4%
7-DTE IV: 130.8%
Expected Move: $3.88
7-DTE Move: $3.12
Days to Exp: 39 (2026-12-18)

Options Flow · All expiries

Call Volume: 3,576
Put Volume: 2,293
P/C Volume: 0.641
BULLISH
Call OI: 32,991
Put OI: 5,908
P/C OI: 0.179
Total OI: 38,899

ATM Options Pricing

ATM Call: $2.90
ATM Put: $0.97
Call %: 17.9%
Put %: 6.0%

Chain Summary

Chain Volume: 5,869
Chain OI: 38,899
Last Updated: 11/9/2026
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 49th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
49%
vs own history
GEX tilt
-0.50
OI-weighted, today
Vanna tilt
+0.01
δ-sensitivity to IV
Charm tilt
-0.42
δ-decay vs time
Charm tilt -0.42: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 9 ATM contracts, 4k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)57.8MediumNov 9
IV Rank (30 DTE)99.3HighNov 9
Straddle Price (30 DTE)$3.88Nov 9
Beta Analysis

Risk Metrics

Beta: 1.6962
Alpha: -86.56%
Correlation: 0.3622
R-Squared: 13.1%
Stock Volatility: 64.5%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own MLYS
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$33.0M
0.02%
#848 of 3716+132.6%13F
Citadel Hedge fund
Ken Griffin
$12.6M
0.01%
#1424 of 6285-22.1%13F
Renaissance Technologies Hedge fund
Jim Simons
$10.2M
0.01%
#1047 of 3138-1.2%13F
Rockefeller Capital Management Family office
Rockefeller family
$7K
0.00%
#4166 of 4729-56.0%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

MLYS Institutional Ownership (13F)

Filings for 2026-06-30 · 68 already for 2026-09-30
Diluted shares outstanding: 79,893,151 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

231 filers99,575,685 shares$2.64B value124.64% of float
# Filer Shares Value % of Total % of Float Period
1 RA CAPITAL MANAGEMENT, L.P. 7,692,750 $207.55M 7.87% 9.63% 2026-06-30
2 Catalys Pacific, LLC 7,799,518 $196.00M 7.43% 9.76% 2026-09-30
3 BlackRock, Inc. Custodian 5,887,038 $158.83M 6.02% 7.37% 2026-06-30
4 Samsara BioCapital, LLC 5,871,018 $158.40M 6.00% 7.35% 2026-06-30
5 FMR LLC Custodian 4,511,689 $121.73M 4.61% 5.65% 2026-06-30
6 State Street Corp 4,141,636 $111.74M 4.24% 5.18% 2026-06-30
7 DEERFIELD MANAGEMENT COMPANY, L.P. 3,958,000 $106.79M 4.05% 4.95% 2026-06-30
8 Vanguard Capital Management LLC 2,756,770 $74.38M 2.82% 3.45% 2026-06-30
9 Laurion Capital Management LP 2,481,698 $62.37M 2.36% 3.11% 2026-09-30
10 T. Rowe Price Associates, Inc. 2,262,476 $61.04M 2.31% 2.83% 2026-06-30
11 ORBIMED ADVISORS LLC 2,110,300 $56.94M 2.16% 2.64% 2026-06-30
12 Capital World Investors 1,997,607 $53.90M 2.04% 2.50% 2026-06-30
13 ARMISTICE CAPITAL, LLC 1,736,000 $46.84M 1.78% 2.17% 2026-06-30
14 Troluce Capital Advisors LLC 1,728,753 $46.64M 1.77% 2.16% 2026-06-30
15 Franklin Resources, Inc. Custodian 1,635,520 $44.13M 1.67% 2.05% 2026-06-30
16 Geode Capital Management, LLC Custodian 1,684,708 $42.35M 1.60% 2.11% 2026-09-30
17 SR One Capital Management, LP 1,563,966 $42.20M 1.60% 1.96% 2026-06-30
18 Bank of America Corp Custodian 1,505,547 $40.62M 1.54% 1.88% 2026-06-30
19 Andera Partners 1,591,917 $40.00M 1.52% 1.99% 2026-09-30
20 SPHERA FUNDS MANAGEMENT LTD. 1,469,971 $39.66M 1.50% 1.84% 2026-06-30
21 Goldman Sachs Group Inc Custodian 1,458,676 $39.36M 1.49% 1.83% 2026-06-30
22 Polar Capital Holdings Plc 1,420,854 $38.33M 1.45% 1.78% 2026-06-30
23 Pictet Asset Management Holding SA 1,376,686 $34.60M 1.31% 1.72% 2026-09-30
24 Millennium Management LLC Custodian 1,221,758 $32.96M 1.25% 1.53% 2026-06-30
25 Ghisallo Capital Management LLC 1,125,000 $30.35M 1.15% 1.41% 2026-06-30
11 filers$46.47M notional
# Filer Notional Value % of Total Period
1 ARMISTICE CAPITAL, LLC $28.06M 60.39% 2026-06-30
2 Caption Management, LLC $3.88M 8.35% 2026-06-30
3 Susquehanna International Group, LLP Custodian $3.61M 7.77% 2026-06-30
4 GROUP ONE TRADING LLC Custodian $3.30M 7.10% 2026-06-30
5 Citadel Advisors LLC Custodian $2.05M 4.40% 2026-06-30
6 Jane Street Group, LLC Custodian $1.91M 4.12% 2026-06-30
7 Troluce Capital Advisors LLC $1.35M 2.90% 2026-06-30
8 Simplex Trading, LLC Custodian $1.26M 2.71% 2026-09-30
9 Millennium Management LLC Custodian $841.78K 1.81% 2026-06-30
10 TUDOR INVESTMENT CORP ET AL $202.35K 0.44% 2026-06-30
11 Coastal Bridge Advisors, LLC $7.90K 0.02% 2026-06-30
7 filers$32.42M notional
# Filer Notional Value % of Total Period
1 Caption Management, LLC $22.98M 70.88% 2026-06-30
2 Susquehanna International Group, LLP Custodian $4.82M 14.86% 2026-06-30
3 Jane Street Group, LLC Custodian $1.70M 5.25% 2026-06-30
4 Citadel Advisors LLC Custodian $1.42M 4.38% 2026-06-30
5 Goldman Sachs Group Inc Custodian $914.62K 2.82% 2026-06-30
6 Simplex Trading, LLC Custodian $479.98K 1.48% 2026-09-30
7 GROUP ONE TRADING LLC Custodian $105.22K 0.32% 2026-06-30

MLYS Insider Trading (Form 4)

Latest: 2026-10-20
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-20 Lonnel Coats Director Award (A) +12,400 — EDGAR
2026-10-20 Kristine Peterson Director Award (A) +12,400 — EDGAR
2026-10-02 Jon Congleton Chief Executive Officer Sell (S) −75,000 $25.46 -$1.91M EDGAR
2026-09-24 Brian Taylor Slingsby Director Sell (S) −104,320 $28.81 -$3.01M EDGAR
2026-09-22 Eric Warren Chief Commercial Officer Mixed
Exer +7,438 · Sell −7,438
 — $20.68 -$110.7K EDGAR
2026-09-17 Daphne Karydas Director Mixed
Sell −3,000 · Exer +3,000
 — $20.30 -$49.7K EDGAR
2026-08-25 Eric Warren Chief Commercial Officer Mixed
Sell −7,437 · Exer +7,437
 — $19.61 -$94.7K EDGAR
2026-08-12 David Malcom Rodman Chief Medical Officer Mixed
Sell −2,170 · Exer +2,170
 — $21.55 -$24.1K EDGAR
2026-08-12 James J. Ferguson III Chief Medical Officer Award (A) +102,400 — EDGAR
2026-07-23 Eric Warren Chief Commercial Officer Mixed
Sell −7,438 · Exer +7,438
 — $20.06 -$101.4K EDGAR
2026-07-20 David Malcom Rodman Chief Medical Officer Mixed
Sell −416 · Exer +416
 — $20.98 -$4.6K EDGAR
2026-07-15 Jon Congleton Chief Executive Officer Sell (S) −10,700 $27.24 -$291.4K EDGAR
2026-07-15 David Malcom Rodman Chief Medical Officer Mixed
Sell −20,407 · Exer +14,058
 −6,349 $19.12 -$454.3K EDGAR
2026-07-10 David Malcom Rodman Chief Medical Officer Mixed
Exer +2,171 · Sell −2,171
 — $23.15 -$31.0K EDGAR
2026-06-17 David Malcom Rodman Chief Medical Officer Mixed
Sell −14,474 · Exer +8,126
 −6,348 $20.00 -$248.1K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

MLYS Insider Holdings

17 insiders · @ $16.17
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Brian Taylor Slingsby Director 7,805,718 $126.22M -$46.03M 9 2026-09-24
2 Srinivas Akkaraju Director 5,877,218 $95.03M $38.10M 8 2026-02-20
3 Samsara BioCapital, L.P. 10%+ Owner 5,674,916 $91.76M $8.10M 1 2025-03-17
4 RA Capital Nexus Fund III, L.P. Director 5,456,521 $88.23M $20.00M 3 2026-02-20
5 RA Capital Healthcare Fund LP Director 1,867,229 $30.19M $17.50M 1 2025-03-17
6 RA CAPITAL MANAGEMENT, L.P. Director 1,867,229 $30.19M $30.00M 3 2025-09-08
7 Jon Congleton Chief Executive Officer 528,621 $8.55M -$17.27M 24 2026-10-02
8 James J. Ferguson III Chief Medical Officer 102,400 $1.66M $0 1 2026-08-12
9 David Malcom Rodman Chief Medical Officer 53,554 $866.0K -$19.98M 57 2026-08-12
10 Adam Scott Levy CFO and Secretary 48,538 $784.9K -$9.06M 16 2026-02-20
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

MLYS Board & Officers

As of SEC filings through Oct 20, 2026

Directors 14

Officers 4

10% owners 3

Changes in the last 10 years (48)
Oct 19, 2026Lonnel Coats became a director
Oct 19, 2026Kristine Peterson became a director
Aug 12, 2026David Malcom Rodman reported in an SEC filing no longer being Chief Medical Officer
Aug 10, 2026James J. Ferguson III became Chief Medical Officer
Mar 4, 2026Eric Warren became Chief Commercial Officer
Feb 20, 2026Srinivas Akkaraju first listed as a 10% owner in an SEC filing
Mar 17, 2025Srinivas Akkaraju no longer listed as a 10% owner in SEC filings
Mar 17, 2025Samsara BioCapital, L.P. reported in an SEC filing no longer being a 10% owner
Mar 17, 2025Samsara BioCapital GP, LLC reported in an SEC filing no longer being a 10% owner
Jun 13, 2024The company announced the departure of Olivier Litzka from the board in an SEC filing
Jun 13, 2024Alexander M Gold became a director
Mar 29, 2024The company announced the departure of Alexander Asam from the board in an SEC filing
Feb 14, 2024Samsara BioCapital GP, LLC first on file as a 10% owner
Sep 13, 2023Glenn Sblendorio became a director
Sep 13, 2023Daphne Karydas became a director
Sep 12, 2023The company announced the departure of Takeshi Takahashi from the board in an SEC filing
Mar 21, 2023Adam Scott Levy listed as CFO and Secretary (previously CFO, Chief Bus. Off. and Secy.) in SEC filings
Feb 16, 2023Rajeev M. Shah no longer listed as a 10% owner in SEC filings
Feb 16, 2023Ra Capital Management, L.p. no longer listed as a 10% owner in SEC filings
Feb 16, 2023RA Capital Nexus Fund III, L.P. no longer listed as a 10% owner in SEC filings
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

MLYS Proposed Insider Sales (Form 144)

Latest: 2026-10-13
Last 30d: 1 filing · $78K notice value  ·  Last 90d: 12 filings · $6.2M notice value · 5 unique filers · 92% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: CATALYS PACIFIC FUND LP (1, $3.0M) · Congleton Jon (1, $1.9M) · Rodman David Malcom (7, $815K) · Warren Eric (2, $402K) · Karydas Daphne (1, $86K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-10-13 Rodman David Malcom Officer 3,542 $78.1K 2026-10-13 Merrill Lynch 10b5-1 EDGAR
2026-09-30 Congleton Jon Officer, Director 75,000 $1.91M 2026-09-30 Merrill Lynch 10b5-1 EDGAR
2026-09-22 CATALYS PACIFIC FUND LP Director 104,320 $3.01M 2026-09-22 Morgan Stanley Smith Barney LLC … — EDGAR
2026-09-21 Warren Eric Officer 7,438 $209.1K 2026-09-21 Merrill Lynch 10b5-1 EDGAR
2026-09-17 Rodman David Malcom Officer 417 $11.7K 2026-09-17 Merrill Lynch 10b5-1 EDGAR
2026-09-15 Karydas Daphne Officer 3,000 $85.7K 2026-09-15 Merrill Lynch 10b5-1 EDGAR
2026-09-14 Rodman David Malcom Officer 7,709 $216.9K 2026-09-14 Merrill Lynch 10b5-1 EDGAR
2026-09-09 Rodman David Malcom Officer 2,171 $67.0K 2026-09-09 Merrill Lynch 10b5-1 EDGAR
2026-08-21 Warren Eric Officer 7,437 $193.2K 2026-08-21 Merrill Lynch 10b5-1 EDGAR
2026-08-17 Rodman David Malcom Officer 417 $10.6K 2026-08-17 Merrill Lynch 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-04 Earnings results · Director or officer change EDGAR
2026-10-29 Material agreement · Agreement terminated EDGAR
2026-10-19 Director or officer change EDGAR
2026-08-11 Earnings results · Director or officer change EDGAR
2026-06-03 Other events EDGAR
2026-06-03 Material agreement · New debt obligation EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-04 0001933414-26-000144 EDGAR
2026-08-11 0001933414-26-000114 EDGAR
ETF Holders
60 ETFs hold MLYS
25 shown · $182.66M total exposure · 0.03% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $54.2M — 2026-09-30
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.03% $24.1M $76.6B 2026-11-06
3 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 0.23% $23.2M $10.0B 2026-11-05
4 VXF Vanguard Extended Market ETF Vanguard 0.02% $18.9M — 2026-09-30
5 VTWO Vanguard Russell 2000 ETF Vanguard 0.05% $9.0M — 2026-09-30
6 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.06% $8.8M $13.7B 2026-11-06
7 SCHA Schwab U.S. Small-Cap ETF Nport 0.03% $7.8M — 2026-08-31
8 IBB iShares Biotechnology ETF iShares (BlackRock) 0.06% $7.0M $11.1B 2026-11-06
9 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.08% $5.3M $6.6B 2026-11-05
10 VHT Vanguard Health Care ETF Vanguard 0.02% $4.6M — 2026-09-30
11 DFAS Dimensional US Small Cap ETF Dimensional 0.01% $3.7M — 2026-11-05
12 SBIO ALPS Medical Breakthroughs ETF Nport 1.16% $2.8M — 2026-08-31
13 DFMC Dimensional US Micro Cap ETF Dimensional 0.02% $1.7M — 2026-11-05
14 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.10% $1.7M — 2026-09-30
15 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $1.6M — 2026-11-05
16 SMLF iShares U.S. Small-Cap Equity Factor ETF iShares (BlackRock) 0.04% $1.5M $4.2B 2026-11-06
17 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $1.4M $93.2B 2026-11-06
18 FFSM Fidelity Fundamental Small-Mid Cap ETF Nport 0.07% $1.0M — 2026-07-31
19 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $913,878 — 2026-08-31
20 LABU Direxion Daily S&P Biotech Bull 3X ETF Direxion 0.16% $833,841 — 2026-11-06
21 ESML iShares ESG Aware MSCI USA Small-Cap ETF iShares (BlackRock) 0.03% $816,537 $2.7B 2026-11-06
22 ONEQ Fidelity Nasdaq Composite Index ETF Fidelity 0.01% $521,757 $10.0B 2026-11-05
23 FHLC Fidelity MSCI Health Care Index ETF Fidelity 0.01% $470,581 $4.0B 2026-11-05
24 RSSL Global X Russell 2000 ETF Global X 0.03% $449,169 — 2026-11-06
25 BBC Virtus Biotech Clinical Trials Etf Nport 0.72% $335,818 — 2026-07-31
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-4.24
TTM Revenue
—
TTM Net Income
$-349.58M
TTM Op. Cash Flow
$-138.79M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30—$-241.07M$-2.85$-32.56M
Q1 '262026-03-31—$-39.34M$-0.47$-39.47M
Q4 '252025-12-31—$-32.23M$-0.35$-37.89M
Q3 '252025-09-30—$-36.93M$-0.52$-28.87M
Q2 '252025-06-30—$-43.27M$-0.66$-30.17M
Q1 '252025-03-31—$-42.21M$-0.79$-45.49M
Q4 '242024-12-31—$-48.95M$-0.98$-66.84M
Q3 '242024-09-30—$-56.34M$-1.13$-50.19M
Q2 '242024-06-30—$-41.01M$-0.83$-30.15M
Q1 '242024-03-31—$-31.51M$-0.70$-19.14M
Q4 '232023-12-31—$-24.39M$-0.63$-28.98M
Q3 '232023-09-30—$-22.76M$-0.57$-19.03M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.34
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-63.5%
ROA
-52.3%
Div Yield
0.00%
FCF Yield
-10.75%
Debt/Equity
0.18
Current Ratio
—
Market Cap
$1.29B
as of 2026-11-09

MLYS vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
NTRA Natera, Inc. Common Stock $45.1B — +36.6% +40.0% 43
APGE Apogee Therapeutics, Inc. Common Stock $10.2B — — +78.2% —
CRNX Crinetics Pharmaceuticals, Inc. $9.0B — +2928.4% +81.8% —
ORKA Oruka Therapeutics, Inc. Common Stock $6.8B — — +272.3% 5
CGON CG Oncology, Inc. Common stock $6.7B — +666.0% +77.9% 100
DNTH Dianthus Therapeutics, Inc. Common Stock $4.8B — −60.8% +128.8% 76
TVTX Travere Therapeutics, Inc. Common Stock $4.8B — +49.4% +28.9% 21
XENE Xenon Pharmaceuticals Inc $3.8B — — −9.4% 52
MLYS Mineralys Therapeutics, Inc. Common Stoc $1.4B — — −54.7% 99
Peer median $6.8B — +49.4% +78.1% 47

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
7.44M
SI % of Float
11.64%
Days to Cover
5.33
Short Vol Ratio
29.7%
Free Float
63.89M
Float %
72.3%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-09-22